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Since the increasing update of the biomolecular scientific literature, biomarkers in stroke have reached an outstanding and
remarkable revision in the very recent years. Besides the diagnostic and prognostic role of some inflammatory markers, many
furthermolecules and biological factors have been added to the list, including tissue derived cytokines, growth factor-likemolecules,
hormones, and microRNAs. The literatures on brain derived growth factor and other neuroimmune mediators, bone-skeletal
muscle biomarkers, cellular and immunity biomarkers, and the role of microRNAs in stroke recovery were reviewed. To date,
biomarkers represent a possible challenge in the diagnostic and prognostic evaluation of stroke onset, pathogenesis, and recovery.
Many molecules are still under investigation and may become promising and encouraging biomarkers. Experimental and clinical
research should increase this list and promote new discoveries in this field, to improve stroke diagnosis and treatment.
1. Introduction
Biomarkers in stroke have reached an outstanding and
remarkable revision in the very recent years, since the
increasing update of the biomolecular scientific literature
in the field. Besides the diagnostic and prognostic role of
some inflammatory markers, such as CRP, IL-6, TNF-𝛼, or
IL-1𝛽, many further molecules and biological factors in the
serum or plasma compartment have been added to the list,
including tissue derived cytokines (myokines, adipokines),
growth factor-like molecules, hormones, andmicroRNAs [1].
The latter ones have become importantmarkers inmany neu-
rodegenerative and neuroimmune disorders, such asmultiple
sclerosis, Alzheimer disease, or Parkinson disease [2–5]. Neu-
roinflammation represents the main mechanism underly-
ing the onset and development of stroke and the peripheral
level of soluble immune factors and immune cells should give
insights either on the onset and pathogenesis of stroke or
on its recovery [6–8]. Poststroke rehabilitation, particularly
following physical exercise and training, generates a crowded
mass of mediators, more than 90, called myokines, which
plays an emerging role in the biomarker field, which should
update the role of plasma or circulating markers in stroke
[9, 10] (see Figure 1).
Stroke risk and even poststroke recovery are strictly
related to endothelial function. A correlation exists between
arterial stiffness index and endothelia function in patients
with acute ischemic stroke [11], while the association of stroke
with hypertension should be better outlined. A recent paper
reported that prestroke use of beta-blockers in hypertensive
subjects did not affect neither stroke severity nor functional
outcome [12]. The relationship between stroke and the car-
diovascular system is particularly complex, as a huge panoply
of different humoral and cellular participants make it highly
complex to comprehend how stroke occurs and how to man-
age its recovery. Some recent papers revealed that the short-
term management of hypertension in hypertensive patients
has a positive effect on the long-term risk reduction of stroke
[13]. Elevated arterial pressure remains a fundamental risk
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Figure 1: Cartoon showing the relationship between brain, muscle, and the immune system during stroke onset and stroke recovery, in order
to highlight possible biomarkers of these events, as described in the text. Damaged brain, either following ischemic or hemorrhagic stroke,
produces a panoply of different biomolecules, mainly BDNF or other neuromodulators, which link brain function with the immune system
(a) and skeletal muscle (b). The first releases cytokines and cellular markers and the second one myokines, many of which interact with
BDNF (c). Many of these myokines modulate the activity of other tissues such as vascular tissue (endothelia), bone, and adipose tissue. Irisin
is a known “browning stimulator” (d). Downstream regulators of these mechanisms are represented by newly discovered miRNAs (e). The
relationship between the activity of a defined biomarker (dose/time in plasma) and stroke recovery can be plotted in a time course curve as
exemplified in (f).
factor also for the pediatric population, in elderly subjects
[14].This would mean that a major concern for rehabilitation
medicine and neurology is the search for the best circulating
markers of this relationship. Many of these markers, actually,
pertain to the ability of the immune system to counteract
with the oxidative and mechanical stress associated with the
cardiovascular function.
The most recent literature on the field stresses on the role
of inflammatory molecules as biomarkers in stroke. Stroke,
which can be simply considered as an injury occurring in
brain when blood flow is cut off, may be of ischemic or
hemorrhagic nature and each year about 800,000 people
experience a new or recurrent stroke, being the fifth leading
cause of death in the United States and about a third in
Italy [15–18]. This circumstance suggests that searching for
new emerging biomarkers for either stroke predictivity, diag-
nosis, or prognosis has come in the spotlight and is asking
for new insights and data from experimental research [19,
20]. Emerging new biomarkers should come from the many
novelties in the scientific field of stroke, which should help
clinicians to improve addressing this pathology and its
dramatic consequences also on the social life and habits.This
review tries to give a state of the art of the topic.
2. Brain Derived Growth Factor (BDNF) and
Other Neuroimmune Mediators in Stroke
The involvement in stroke of BDNF, a 13 kDa protein that
belongs to the neurotrophin family, emerged some years ago.
In particular low serum concentration of BDNF, particularly
in the acute phase of ischemic stroke, is considered a factor
of poor prognosis for the functional status of patients [57].
Physical exercise should ameliorate this circumstance, even
by increasing the hippocampal level of BDNF in the early
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stages of a stroke (cerebral embolism) [58].The enhancement
of BDNF seems to be related to improvements in stroke
recovery, even in animal models [59, 60], which show how
social interactions are fundamental in the poststroke recovery
[61]. BDNF increase in the hippocampus may improve also
poststroke depression following estrogen-based therapy [37],
a role that is also reached by physical exercise and muscular
training [62]. Therefore, BDNF may be a good candidate
to follow stroke development, even in chronic poststroke
subjects, where circulating BDNF is very low with respect to
controls [47, 48]. Besides BDNF further neurotrophins were
recently involved in stroke and may fulfil the list of potential
biomarkers.
Neurotrophin-3 has a major role in both traumatic and
ischemic injury of the brain, such as in stroke. It is produced
by neuroglia as an adaptation factor to hypoxic conditions
and, together with proinflammatory cytokines such as IL-6
and TNF-𝛼, it participates in the brain response to ischemic
injury [49]. In mouse models, an upregulation of the neu-
rotrophic receptor p75 (NTR) in striatal neurons during an
ischemic damage was reported [40]. Neurotrophins should
act with biochemical factors the ability of which is to reg-
ulated endothelial and vascular function. Actually, vascular
endothelial growth factor (VEGF) has been recently associ-
ated with BDNF as a biomarker in stroke [63, 64], though
with some criticism [39]. In animalmodels, the neurotrophin
ciliary neurotrophic factor (CNTF), which is endogenously
upregulated in a stroke onset, mediates the neurogenesis
and an anti-inflammatory process [41]. The correct neuron-
astrocyte interaction dampens CNTF release, which is upreg-
ulated by astrocytes therefore during a traumatic or ischemic
damage to this integrin-mediated linkage [42]. To date there
are no evidence reporting the role of plasmatic CNTF in
stroke, though the circulating levels of this neurotrophin
have gained much more importance in the study of patients
with amyotrophic lateral sclerosis [43]. Still, in rat models,
neurotrophin-4 increases its serum levels after a stroke event
and exhibits the same properties of BDNF, as it is likewise a
ligand of trkB [65]. Neuropeptide biology is moreover very
rich of suggestions in order to retrieve emerging biomarkers
for stroke. Yet, genetics should be involved in these issues, as
genetic polymorphism highly influences the analytical per-
formance of whatever would be introduced as a biomarker,
particularly for neuropeptides. For example, neuropeptide
Y may be a good prognostic biomarker in subjects with
certain gene promoter polymorphisms [45]. Proenkephalin
(PENK), or proenkephalin A, as proenkephalin B is known as
prodynorphin, is a neuropeptide of recent introduction in the
biomarker list. Its plasma level may be used as an indicator of
prognostic outcome of stroke, as elevated concentrations in
the bloodstream correlate with exacerbation of the cerebral
injury [66, 67]. The neuropeptide pituitary adenylate-cyclase
activation protein (PACAP) is involved, asmany other factors
here described, in the poststroke neurogenesis [68]. Also
PACAP increase in plasma may be used as a prognostic
marker of stroke, as an increase has been associated with
severity of intracranial hemorrhage [69]. Neuromediators in
stroke, detectable in the bloodstream and being considered
as emerging biomarkers, should suggest that the ability to set
a panoply of biomarkers for diagnosis and prognosis of stroke
is a fundamental point at issue in the clinical research of this
pathology.
3. Bone-Skeletal Muscle Biomarkers in Stroke
The involvement of the skeletal and muscular function,
and its relationship, in stroke prevention and management,
should be taken into account when addressing the issue of
stroke biomarkers, as skeletalmuscle undergoes deep changes
in poststroke events [70]. Furthermore, myokines play a
major role in the cross-talk bone-muscle [27, 71]. The role
of skeletal muscle in stroke is of major interest. Markers of
inflammation increase both systematically and locally in the
skeletal muscle during stroke, while the anti-inflammatory
feedbackmechanism involves bothmyokines and the cholin-
ergic anti-inflammatory pathway, which should be activated
by physical exercise [9]. Myokines are muscle derived factors,
with a role similar either to cytokines or growth factors,
which modulate the complex relationship between skeletal
muscle and other fundamental compartments, such as bone
or adipose tissue, and whose upregulation is dependent on
subject’s physical exercise [21, 22, 27, 72]. Their activity in
stroke should suggest a possible role as biomarkers of stroke
pathogenesis and/or recovery [73].
3.1. Irisin. Irisin, otherwise known with its precursor name,
that is, fibronectin type III domain-containing protein 5
(FNDC5), is a muscular trans-membrane protein, with a
fibronectin type III-like ectodomain that can be cleaved
giving the soluble molecule known as irisin [74]. This
myokine fundamentally regulates the cross-talk skeletal
muscle-adipose tissue [71]. Serum levels of irisin increase
with training and physical exercise [75, 76]; therefore it may
appear intriguing to ascertain if irisin may be involved as a
possible and promising serum marker in poststroke training
and stroke recovery or neuromuscular rehabilitation. To the
best of our knowledge, there are no or very few reports
showing or suggesting a relationship between irisin and
stroke. During heart failure (HF), the expression FNDC5 was
related to an improvement in the aerobic performance in
HF patients, therefore suggesting that FNDC5 may work as
a hormone counteracting stress coming from injury, tissue
damage, hypoxia, and inflammation [77]. Its association with
training is yet much more encouraging. Together with other
myokines and neuromodulators, irisin should participate in
the regulation of resistance training periodization, partic-
ularly in subjects with sedentary or rarely active life [78].
Furthermore, physical exercise induces the hippocampal
expression of the brain derived neurotropic factor (BDNF),
through a PGC-1𝛼/FNDC5 pathway, that is, PGC-1𝛼 (which
is amarker ofmitochondrial function and biogenesis), during
endurance exercise in mice, which elicits the expression of
the neuronal gene for FNDC5, which in turn induces BDNF
expression [79]. This relationship irisin precursor, namely,
FNDC5, and BDNF may be of fundamental importance in
the comprehension of the role of training in stroke [80],
particularly because physical exercise induces BDNF but also
synapsin I in the hippocampal trisynaptic circuit [81]. BDNF
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induces local synaptic plasticity [82] and more interestingly
cyclin-dependent kinase 5 (Cdk5), a serine/threonine kinase
involved in the rescue of synaptic plasticity [83], is involved in
the BDNF-stimulated dendritic growth in hippocampus [84].
In poststroke patients, the role of Cdk5 has been associated
with the long-term postischemic neurodegeneration and
Cdk5 might be a pharmacological target; its inhibition or
gene silencing increases the expression of BDNF in the
hippocampal neurons [85]. The loss of this serine/threonine
kinase in the nucleus accumbens reduces the ability to sustain
a muscular physical exercise [85]. The relationship between
the different degrees of the muscular activity (training,
sustained and endurance physical exercise, moderate aerobic
exercise, etc.) and the newly incoming biomarkers is still
puzzling, particularly if related to poststroke rehabilitation.
The role of irisin and its precursor FNDC5 in stroke recovery
with training is quite far to be fully elucidated. As far as irisin
is concerned, both muscle and brain express this hormone,
which even participates in neurological and neuropsychiatric
function such as regulation of behaviour and the mechanism
of boosting reward-related learning and motivation [86]
and is considered as one of the major linkers between
muscular activity and brain [23]. Both irisin and BDNF are
possible candidates as markers of sarcopenia [24], together
with the transforming growth factor-𝛽 (TGF-𝛽), follistatin,
insulin-like growth factor-I (IGF-1), fibroblast growth factor-
2 (FGF-2), osteoglycin, FAM5C, interleukin (IL-6), leukemia
inhibitory factor (LIF), IL-7, IL-15, monocyte chemoattrac-
tant protein-1 (MCP-1), ciliary neurotrophic factor (CNTF),
osteonectin, and matrix metalloproteinase 2 (MMP2), which
affect also bone cells [27]. It is tempting to speculate that
serum irisin would be an emerging biomarker in the rela-
tionship muscular activity/brain function and possibly an
emerging biomarker also for stroke recovery.
3.2.Myostatin. Thismyokine, known also as growth differen-
tiation factor 8 (GDF-8), is a member of the TGF-𝛽 protein
family [25, 27] and has been recently related to the role and
activity of GDF-11, with which it shares some similarities
[25]. Myostatin is associated with muscle catabolism and
actually antibodies against myostatin were considered to
prevent sarcopenia, cancer cachexia, and muscle wasting
disorders [26, 87]. People who survive stroke experience
a disproportionate atrophy of their muscle mass or other
detrimental tissue changes in the composition on the paretic
side. Recent evidence supports the suggestion for a funda-
mental role of myostatin in these subjects, as an increase in
myostatin mRNA was reported in the paretic thigh, while
a reduction was observed following resistive training [88].
The serum level of myostatin, which is a negative regulator of
muscle growth, has been associated with muscle function in
a maintenance grip strength; that is, higher serum myostatin
has been related to lower muscle function [89] and is a
marker of muscle wasting [90]. Myostatin shares with irisin
or FNDC5 a role in the browning phenomenon of the adipose
tissue; therefore this myokine, as well as irisin, has a role
in glucose and fat metabolism, besides muscle function [91].
Thiswould suggest a possible relationship between stroke and
nutrition in the myokine activity [92, 93]. Serum myostatin,
as a possible biomarker in stroke-related disorders, has been
reported for myocardial ischemia-related injury, as a cardiac
myostatin upregulation immediately occurs after myocardial
ischemia and participates in the ubiquitin-proteasome degra-
dation of proteins, via the atrogin andMuRF1 involvement, in
the skeletal muscle [94]. To the best of our knowledge, there
are very few reports about the association of myostatin with
poststroke neurorehabilitation, but evidence should suggest
that this myokine may be upregulated following stroke
and downregulated with muscular training. Animal models
support this hypothesis. Muscle is involved in maintaining
the bonemineral content and in electrical muscle stimulation
following sciatic neurectomy in rats; muscle fibers downregu-
lated myostatin gene expression, a model that should suggest
the downregulation of this myokine in stroke-derived paretic
limbs [95]. Cerebral ischemia causes also the activation of
the bone morphogenetic protein (BMP)/Smad/5/8 signaling
in muscle atrophy occurring following stroke. The ubiquitin-
proteasome degradation of muscle proteins in paretic limbs
following the severe sensorimotor deficits after cerebral
ischemia involves a biomolecular mechanism in muscle
fibers that inhibits the Akt/mTOR pathway and increases,
besides myostatin, many actors of the ubiquitin-proteasome
degradation such as muscle RING finger-1 or MuRF1, muscle
atrophy F-box (MAFbx), and muscle ubiquitin ligase of SCF
complex in atrophy-1 or Musa1 [96]. This evidence may
suggest even a role of myostatin as a prognostic marker for
stroke.
3.3. Cytokines and Muscle-Related Immune Mediators. Skele-
tal muscle is one of the major producers of interleukin-6 (IL-
6), which contributes with other factors such as irisin to the
fine regulation of bone metabolism and adipose tissue home-
ostasis after physical exercise [10, 97, 98]. The relationship
between IL-6 and stroke is established principally by neuroin-
flammatory mechanisms in the CNS, where the expression
of genes such as IL-6, besides myeloperoxidase (MPO), IL-
1𝛽, and TNF-𝛼, is fundamental for stroke susceptibility [99]
but also myocardial stroke generates a peripheral proinflam-
matory response in skeletal muscle [100]. In chronic heart
failure trainingmuscular exercise reduces muscle production
of IL-6, TNF-𝛼, IL-1𝛽, and iNOS [101] although thosemarkers
involved in muscle atrophy, that is, atrogin and MuRF1,
do not change their expression pattern in skeletal muscle
[102], assessing that this model is not fully comparable
to stroke-related muscle disorders. Following stroke huge
panoply of proinflammatory cytokines that are released in
the bloodstream and detectable in the serum, besides IL-
6 and TNF-𝛼, also IL-10, IL-4, IL-17, IL-23, and TGF-𝛽
increase [103]. Low frequency electrical stimulation together
with acupuncture in denervation muscle induced atrophy in
mice, reduced the expression of myostatin, and transiently
increased the level of inflammation by enhancing the expres-
sion of IL-5, TNF-𝛼, arginase-1 expressing macrophages (M1-
type), and muscle specific microRNA, that is, miRNA-1 and
miRNA-206, but also upregulated IGF-1 expression [104, 105].
This should suggest that inflammation in muscle is initially
triggered to attenuate muscle degeneration and atrophy, by
activating, for example, mitochondria-biogenesis markers,
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such as PGC-1𝛼 and autophagy [106–108]. Factors inhibiting
autophagy in muscle fibers and the intracellular accretion
of unfolded, damaged proteins may lead to apoptosis and
muscle atrophy [109]. The intriguing relationship between
muscle inflammation and PGC-1𝛼 is finely modulated. At
least, as emerging from in vitro heart models, PGC-1𝛼 is
upregulated following short-term exercise and interestingly
an anti-inflammatory stimulus may reduce the activity of
PGC-1𝛼 by attenuating its downstream effectors, such as
NRF-1 and several respiratory genes, as most probably oxida-
tive stress generated by either inflammation or muscular
exercise is a main trigger of PGC-1𝛼 [110]. Mediators of this
muscle response include several immune mediators besides
IL-6. Interleukin 15 (IL-15) inducesmitochondrial activity, via
a PPAR-𝛿 signaling during physical exercise [111]. Although
there seems to be lack of evidence reporting a role of
IL-15 in muscle atrophy following stroke, the most recent
reports about this cytokine in this field suggest a possible
involvement in this mechanism. At least, in diabetic rats,
resistance training increasing both muscle and serum levels
of IL-15 [112] and IL-15 is one of the main protective factors
in sepsis-induced muscular wasting and proteolysis in mice
[113]. In this sense, IL-15 should play a protective role against
stroke or its dependent effects, as likely as further cytokines
such as IL-19 [114] or IL-33 [115]. Despite its well-known
anti-inflammatory role, IL-10 has been recently associated
with worsening of muscle atrophy. Even a short bed rest in
aged patients with leg leanmass or muscle wasting associated
symptoms increases some proinflammatory cytokines and
also IL-10 [116]. Furthermore, an excessive IL-10 response
may even worsen stroke recovery, depending on genetics
and sex [117, 118]. Actually, the inflammatory participation in
stroke recovery should be profoundly revised. Interleukin 6
is still associated with worsening in muscle activity [119, 120],
assessing the detrimental role of inflammatory cytokines in
stroke-dependent muscle damage. But, as an example, anti-
inflammatory drugs should act as a double-edged sword,
both exacerbating brain injury and helping the pathway
to poststroke recovery, suggesting the existence of more
complex machinery in the neuromuscular rehabilitation
[121]. For example, interleukin 17A (IL-17A), produced by
𝛾𝛿T, cells was initially thought to have detrimental action
in the pathogenesis of acute ischemic stroke but a deeper
focusing onto its activity showed that IL-17A participates
in neuronal differentiation, synaptogenesis, and spontaneous
recovery following ischemic stroke [122]. Both IL-17A and
IL-23 failed in being associated with biomarkers in muscle
damage, following physical exercise [123]. Fundamentally,
muscle produces cytokines that are widely expressed in the
innate and adaptive immune system, such as IL-6, IL-8, IL-
10, IL-1ra, TNF-𝛼, MCP-1, IL-1𝛽, IL-12p35/p40, and IL-15
[124]. Particularly for IL-1 receptor antagonist (IL-1ra) it is
well-known that this cytokine reverses immune suppression
associated with stroke, generating concerns about the effect
of immunosuppression during the acute phase of stroke [28].
Yet, there are controversial opinions about the therapeutic
effect of this anti-inflammatory cytokine in stroke [29, 30];
probably one must distinguish the effect of systemic IL-1ra
from local (e.g., skeletal muscle, myocardium). However, a lot
of molecules with a growth factor-like activity have come in
the spotlight as potential biomarkers in stroke.
3.4. Follistatin-Like 1, Insulin Growth Factors, and Other
Myokines. Follistatin, known also as activin-binding protein
(ABP), is considered as an antagonist of myostatin. Recent
reports showed that the ratio myostatin to follistatin is a
good marker of the denervated muscular atrophy and its
recovery [125]. Circulating follistatin levels are correlated
with muscular mass in healthy individuals [126]; therefore its
presence in the peripheral blood should be interpreted as a
positive prognostic marker of the recovery of muscle damage
and atrophy following stroke, a hallmark of several myokines
[73, 127, 128]. Follistatin-like 1 is a myokine which promotes
revascularization and endothelial cell function following an
ischemic injury [129]. Follistatin-like 1 (FSTL1) is a protein
very similar to follistatin, which does not bind to activin A,
but rather BMP4 and TGF-𝛽 [130, 131]. The neuroprotective
role of FSTL1 has been reported in rats, where the glycopro-
tein is able to repair and improve neuron deficits inducing
Akt phosphorylation and hence its receptor disco-interacting
protein 2 homolog A (DIP2A) activation [132, 133]. FSTL1 is
a marker of remodelling also in cardiac function, where in
subjects with heart failure an increase in the serumFSTL1was
observed [31]. Actually, FSTL1 has been recently considered
an independent circulating biomarker of inflammation and
oxidative stress and likewise hsCRP, associated with markers
predictive of stroke [32]. Despite its proinflammatory-like
nature [130], FSTL1 is a cardioprotective molecule, which
is upregulated following exercise training, particularly after
myocardial infarction [134] and which modulates vascular
remodelling [33].
Serum level of FSTL1 may give fundamental insights
on the individual’s response to ischemic stress. Pigment
epithelium derived factor (PEDF) known as serpin F1, is a
myokine with neurotropic activity, which has been recently
associated, as a neuroprotective and antiangiogenic agent
in animal models, with ischemic stroke [34, 135]. However,
to the best of our knowledge, there are yet no data about
the association between serum PEDF and stroke-related
disorders, particularly for muscle. Rat models showed that
PEDF induces the production of inflammatory chemokines
such as MIP-2 and MIP-3𝛼 in microglia [136]. The myokine
dipeptidyl-peptidase 4 (DPP4) has recently come in the
spotlight because its inhibition, as well as the use of glucagon-
like receptor 1 (GLP-1) agonists, leads to an antistroke effect
[137, 138] and a cardioprotective role [139]. During physical
exercise, DPP4 inhibitors improve mitochondrial biogenesis
andmuscle activity through the activation of GLP-1 signaling
[140]. Yet, this myokine should act at amore systemic level, in
the energetic balance of the organism, as their inhibitors are
able to act in a similar way to sulfonylureas or pioglitazone for
diabetes [141]. Insulin-like growth factors (IGFs), particularly
with the involvement of CXCR4, are fundamental molecules
in remodelling, even after stroke [50, 142, 143]. The serum
level of IGF-1 in elderly men with muscle frailty has been
considered as positive prognostic marker, also for bone min-
eral density [51]. IGF-I and IGF-II are important myokines
recently related to stroke [52].The relationship between IGF-1
6 Neural Plasticity
and physical training is particularly intriguing, as serum total
IGF-1 in response to a resistance exercise is highly variable
and depends on the subject’s body mass [144]. However,
recent reports indicate that IGF-1 has a major role, together
with BDNF, in neuroplasticity and in the recovery of the
neuromuscular function following stroke by active muscle
exercise [145–147], although an excess in IGF-1 production
can induce neuroinflammation and exacerbation of stroke
effects, as occurring following treatment with apolipoprotein
A-1 mimetic peptide, which reduces white matter damage
from stroke [148].Therefore, besides the complexity of events
related to IGF-1 activity, even when associated with BDNF,
for many emerging myokines a possible role as biomarkers
in stroke yet needs confirmation in clinical studies, despite
the encouraging evidence coming from in vitro or animal
studies. Usually, the serum level of IGF-1 in patients with
stroke-derived intracerebral hemorrhage during admission
(hospitalization) is lower than healthy controls, while VEGF
and hepatocyte growth factor (HGF) are higher [149]. Further
factors related to IGFs have been recently associated with
stroke and may suggest emerging biomarkers in this pathol-
ogy. A recent study showed that not only low levels of IGF-1
were associated with an unfavourable functional outcome of
stroke but also the level of insulin-like growth factor binding
protein-3 (IGFBP-3) [35]. More favourable outcomes should
be yet associated with the evaluation of the decrease in the
IGF-1 ratio and with IGFBP-3, rather than with serum levels
of IGF-1 [150]. Actually, amore complex relationship between
IGF-1, IGF-II, IGFBP-1, and IGFBP3 should give important
insights on the risk of ischemic stroke [151, 152].This complex
pattern is a hallmark of many myokines involved in stroke.
Myokines includes cytokines, hormone-like molecules, and
growth factors. Fibroblast growth factor 21 (FGF21) is a
myokine, which may be important in detecting subclinical
atherosclerosis, which may be a pathogenetic cause of stroke
[153]. FGF21 is related to metabolism, stress response, mito-
chondria function, and insulin resistance, as serum levels
of FGF21 are elevated in certain types of mitochondria dys-
function, particularly in the muscle [154, 155]. Some reports
have investigated also its relationship with bone physiology
but the topic asks for further insights [156, 157]. It would
be interesting to ascertain if serum level of FGF21 may be
associated with positive outcome given by physical exercise.
This has been reported for metabolic syndrome [158], yet not
for poststroke training; then FGF21 may be suggested as an
indirect biomarker.
Table 1 summarizes most of the assessed and emerging
biomarkers in stroke onset and recovery.
4. Cellular Biomarkers and
Immunity of Stroke
The role of the immune system in stroke and in its
recovery-rehabilitation process, using physical training or
others, includes both soluble factors (cytokines, chemokines,
myokines, adipokines, andneuroimmunokines) and immune
cells. Immune cells may be investigated mainly using flow
cytometry and can give fundamental insights on the role
and activity of innate immunity in the remodelling process
following stroke [55, 56, 103, 159–161]. Some circulating
cytokines and reactive molecules, such as interleukin 11 (IL-
11), are considered important markers of ischemic stroke
[162, 163], though some consideration should be taken into
account about the role of the different subtypes of stroke
[164]. Cellular signals, such as the immunoproteasome, are
correlatedwith ischemic stroke with intracranial hemorrhage
[165]. The phenotypic subsetting of the different lymphocyte
populations would be an interesting biomarker of stroke
and stroke recovery. For example, a peripheral persistence of
CD4+CD28− T cells (CD28 null cells) has been reported in
acute ischemic stroke [166], assessing previously reported evi-
dence [167]. Fox P3+CD25+CD4+ regulatory T cells (Tregs)
are presumably involved in stroke-related events [168]. In
this regard, the program death 1 ligand (PF-L1) on Tregs
should have a major role in neuroprotection against cerebral
ischemia, as it mediated the suppressive action exerted by
Tregs on metalloproteinase 9 (MMP9), which is released
by inflamed neutrophils [169]. Innate immunity plays a
fundamental role in stroke. It has been recently reported that
nucleotide binding oligomerization domain- (NOD-) like
receptors (NLRs), which are a class of cytoplasmic pattern-
recognition receptors, are upregulated and highly expressed
in a mouse model of ischemic stroke [170]. Recent pharma-
cological strategies have taken into consideration the innate
immune hallmark of inflammation in stroke. This allowed
researchers to realize that the anti-inflammatory mechanism
induced by the damaged brain may be a good target for ther-
apy. The cholinergic anti-inflammatory pathway, when mod-
ulated by 𝛼7-nicotinic acetylcholine receptor (𝛼7-nAChR)
ligands, may facilitate stroke recovery. By using a polychro-
matic flow cytometry approach, it is possible to investigate
how circulating leukocytes change their surface phenotypes
and subtypes and/or their amount in relation to stroke-
associated-events. Invariant natural killer T cells (iNKT)
infiltrate mouse ischemic hemisphere in animals undergoing
an ischemic stroke [171, 172]. Alpha-galactosyl ceramide
(𝛼GC), which specifically activates iNKT, is requested to
promote the protective role of iNKT in myocardial stroke
[173], a circumstance that would be suggested also for brain
stroke [172]. A high number of circulating NK cells within
the first hours of an ischemic stroke, particularly if followed
by a rapid falling down of other lymphocyte subsets, may
indicate a possible risk of pejorative inflammatory disorders
in stroke patients [174]. Infiltrations of NK cells in brain
occur also in human during ischemic stroke, where cells are
probably activated by IP-10 [175]. This evidence assesses the
role of innate immune cells infiltration in the development
of stroke-related damage. Stroke-induced lymphopenia is
related to a reduction of circulating high mobility group
protein B1 (HMGPB1) and by the activity of T cells [176].
CD4+ T cells, together with CD8+, 𝛾𝛿-T cells, and Tregs,
change their peripheral pattern following stroke [177]. Very
recently, Klehmet et al. reported that stroke induces defined
alterations in thememoryT cell compartment [178]. Gamma-
delta T cells, which are with Th17 the main producers of
IL-17A, increase dramatically during ischemic stroke [179].
Leukocyte subtypes that dynamically should change with
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stroke and change their surface markers are very different
depending on the time of stroke onset and its subtype.There-
fore, this evidence should render particularly complex any
interpretation of the flow cytometry panel used to highlight
the percentage and nature of the various lymphocyte subsets
in the bloodstream. B cell compartment is also involved in
stroke biology. Particularly, for pre-B cells, the released factor
nicotinamide phosphoribosyltransferase (NAMPT), more
simply known as pre-B-cell colony-enhancing factor (PBEF),
plays a fundamental role in the mitochondrial survival and
biogenesis after ischemic damage, protecting neurons from
apoptosis [180]. B cells in stroke showedheterogeneity in their
function and subtypes and participate in prestroke neuro-
protective mechanisms [181]. Regulatory B cells contribute to
limiting the inflammatory events occurring in CNS following
stroke and IL-10 secreting B cells appear to have the major
role in this mechanism [182]. Regulatory T cells have also a
fundamental function in addressing stroke-related damage,
particularly in poststroke recovery [183]. Actually, their role
in this recovery process has suggested Tregs as a cellular
therapy in stroke [170].
Much lesser importance has been given to circulat-
ing granulocytes in their possible relationship with stroke.
Peripheral eosinophils have been associated with stroke, as
the eosinophil count appears to have a fundamental impact
on the outcome of stroke [184]. Blood neutrophil counts
appeared to be associated with intracranial hemorrhage
following stroke but this association was recently criticized
[185, 186]. A role for basophils in stroke was reported
several years ago but there is no further association to date,
although mast cells are probably the early responders in
the regulation, following ischemic stroke, of the blood-brain
barrier [187, 188]. At least in mouse models, the CD36+
monocyte/macrophage system is involved in the poststroke
recovery phase, leading to a correct phagocytosis [189].
In these models, monocyte-derived macrophages exhibit a
repair function in the poststroke event [190]. Very recently,
the role of monocytes in ischemic stroke has been thoroughly
reviewed [191]. Interestingly, monocytes recruited to the
ischemic site inmouse differentiate to an alternative activated
macrophage (AAM) or M2-macrophage [56].
Particular interest has been recently devoted to brain den-
dritic cells in stroke events [192]. However, also antigen-pre-
senting cells (APCs) in peripheral blood should give impor-
tant insight on immune response to stroke and the mech-
anism of tolerance [193]. During cerebral focal ischemia a
reduced peripheral costimulatory activity has been observed
[194]. Stroke generates imbalance in the acquired immune
response and a decrease in circulating dendritic cells [195].
5. MicroRNAs as Biomarkers in Stroke
MicroRNAs are the latest novelty in the emerging role of
biomarkers in stroke [196]. These short modulatory RNA
fragments play a fundamental role in the management of
stroke, as much as that polymorphism in the microRNAs
miRNA-130b, miRNA-200b, and miRNA-495 affects stroke
susceptibility and the level of poststroke outcome [197].
MicroRNAs participate in the regulation of blood-brain
barrier and in the function of microglia and astrocytes [198,
199]. Peripheral microRNAs are promising and emergent
biomarkers for stroke [200]. Some miRNAs play prognostic
or high diagnostic value to evaluate or predict stroke onset
and development.
For example, low level of serum miRNA-320b is a high-
risk factor for carotid atherosclerosis, a prodromic event
possibly leading to cerebral ischemia and stroke [201], while
miRNA-146a correlates with neuroprotection from cerebral
ischemia [202]. The downregulation of miRNA-30a reduces
ischemic injury via the enhancement of the beclin-1mediated
autophagy [203]. This neuroprotection role is exerted also
by the downregulation of miRNA-181b, at least in the mouse
model, via the involvement of the heat shock protein 45 and
the ubiquitin carboxyl-terminal hydrolase isozyme L1, a role
shared also by miRNA-30a [204, 205]. A neuroprotective
role is exerted by miRNA-134 by targeting another heat
shock protein, namely, HSPA12B [36]. Mesenchymal stem
cells (MSC) may be primed by serum from stroke patients
and this priming upregulates the expression of miRNA-20a,
which in turn promotes MSC proliferation by regulating
cell cycle and p21 CDKN1A [38]. This should suggest that
miRNA-20a participates in the remodelling of damaged
tissue after stroke. MicroRNAs as a biomarker for stroke
may use either cerebrospinal fluid (CSF) or peripheral blood.
After stroke some miRNAs, such as let-7c an miRNA-221-
3p, are upregulated in CSF, while, in whole blood, where
more than 250 differentmiRNAswere detected,miRNA-151a-
3p and miRNA-140-5p were upregulated while miRA-18b-5p
was downregulated [44, 46, 53, 54, 206–210].
6. Conclusions
Biomarkers in stroke represent a possible challenge in
the diagnostic and prognostic evaluation of stroke onset
and pathogenesis and in poststroke recovery. Many of the
molecules described in the text are still under investigation
and may become promising and encouraging biomarkers,
either diagnostic or prognostic emerging biomarkers. In this
perspective, research is actually asking for further insights,
particularly about newly incoming myokines (for stroke
recovery following muscular training) but also for those
neuropeptidergic and neurotropic molecules, which should
be better suited to fit as circulating biomarker in stroke
rehabilitation due to nonmuscle exercise. Experimental and
clinical research should increase this list and promote new
discoveries in this field, in order to improve stroke diagnosis
and treatment.
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